Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
1.
Allergy ; 77(5): 1486-1498, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-34689335

RESUMEN

BACKGROUND: Atopic dermatitis (AD) is a frequent and heterogeneous inflammatory skin disease, for which personalized medicine remains a challenge. High-throughput approaches have improved understanding of the complex pathophysiology of AD. However, a purely data-driven AD classification is still lacking. METHODS: To address this question, we applied an original unsupervised approach on the largest available transcriptome dataset of AD lesional (n = 82) and healthy (n = 213) skin biopsies. RESULTS: Taking into account pathological and physiological state, a variance-based filtering revealed 222 AD-specific hyper-variable genes that efficiently classified the AD samples into 4 clusters that turned out to be clinically and biologically distinct. Comparison of gene expressions between clusters identified 3 sets of upregulated genes used to derive metagenes (MGs): MG-I (19 genes) was associated with IL-1 family signaling (including IL-36A and 36G) and skin remodeling, MG-II (23 genes) with negative immune regulation (including IL-34 and 37) and skin architecture, and MG-III (17 genes) with B lymphocyte immunity. Sample clusters differed in terms of disease severity (p = .02) and S. aureus (SA) colonization (p = .02). Cluster 1 contained the most severe AD, highest SA colonization, and overexpressed MG-I. Cluster 2 was characterized by less severe AD, low SA colonization, and high MG-II expression. Cluster 3 included mild AD, mild SA colonization, and mild expression of all MGs. Cluster 4 had the same clinical features as cluster 3 but had hyper-expression of MG-III. Last, we successfully validated our method and results in an independent cohort. CONCLUSION: Our study revealed unrecognized AD endotypes with specific underlying biological pathways, highlighting novel pathophysiological mechanisms. These data could provide new insights into personalized treatment strategies.


Asunto(s)
Dermatitis Atópica , Adulto , Humanos , Índice de Severidad de la Enfermedad , Piel/patología , Staphylococcus aureus/genética , Transcriptoma
2.
Proc Natl Acad Sci U S A ; 116(33): 16463-16472, 2019 08 13.
Artículo en Inglés | MEDLINE | ID: mdl-31346092

RESUMEN

Heterozygous in-frame mutations in coding regions of human STAT3 underlie the only known autosomal dominant form of hyper IgE syndrome (AD HIES). About 5% of familial cases remain unexplained. The mutant proteins are loss-of-function and dominant-negative when tested following overproduction in recipient cells. However, the production of mutant proteins has not been detected and quantified in the cells of heterozygous patients. We report a deep intronic heterozygous STAT3 mutation, c.1282-89C>T, in 7 relatives with AD HIES. This mutation creates a new exon in the STAT3 complementary DNA, which, when overexpressed, generates a mutant STAT3 protein (D427ins17) that is loss-of-function and dominant-negative in terms of tyrosine phosphorylation, DNA binding, and transcriptional activity. In immortalized B cells from these patients, the D427ins17 protein was 2 kDa larger and 4-fold less abundant than wild-type STAT3, on mass spectrometry. The patients' primary B and T lymphocytes responded poorly to STAT3-dependent cytokines. These findings are reminiscent of the impaired responses of leukocytes from other patients with AD HIES due to typical STAT3 coding mutations, providing further evidence for the dominance of the mutant intronic allele. These findings highlight the importance of sequencing STAT3 introns in patients with HIES without candidate variants in coding regions and essential splice sites. They also show that AD HIES-causing STAT3 mutant alleles can be dominant-negative even if the encoded protein is produced in significantly smaller amounts than wild-type STAT3.


Asunto(s)
Proteínas de Unión al ADN/genética , Síndrome de Job/genética , Sitios de Empalme de ARN/genética , Factor de Transcripción STAT3/genética , Adulto , Alelos , Linfocitos B/metabolismo , Linfocitos B/patología , Preescolar , Exones/genética , Femenino , Regulación de la Expresión Génica/genética , Heterocigoto , Humanos , Síndrome de Job/patología , Mutación con Pérdida de Función/genética , Masculino , Persona de Mediana Edad , Linfocitos T/metabolismo , Linfocitos T/patología
3.
Clin Infect Dis ; 72(2): 319-322, 2021 01 27.
Artículo en Inglés | MEDLINE | ID: mdl-33501967

RESUMEN

A time series analysis of 871 543 pediatric emergency visits revealed that the coronavirus disease 2019 (COVID-19) lockdown and school closures were associated with a significant decrease in infectious diseases disseminated through airborne or fecal-oral transmission: common cold, gastroenteritis, bronchiolitis, and acute otitis. No change was found for urinary tract infections.


Asunto(s)
COVID-19 , Pandemias , Niño , Control de Enfermedades Transmisibles , Humanos , SARS-CoV-2 , Instituciones Académicas
4.
Proc Natl Acad Sci U S A ; 115(34): E8007-E8016, 2018 08 21.
Artículo en Inglés | MEDLINE | ID: mdl-30072435

RESUMEN

Isolated congenital asplenia (ICA) is the only known human developmental defect exclusively affecting a lymphoid organ. In 2013, we showed that private deleterious mutations in the protein-coding region of RPSA, encoding ribosomal protein SA, caused ICA by haploinsufficiency with complete penetrance. We reported seven heterozygous protein-coding mutations in 8 of the 23 kindreds studied, including 6 of the 8 multiplex kindreds. We have since enrolled 33 new kindreds, 5 of which are multiplex. We describe here 11 new heterozygous ICA-causing RPSA protein-coding mutations, and the first two mutations in the 5'-UTR of this gene, which disrupt mRNA splicing. Overall, 40 of the 73 ICA patients (55%) and 23 of the 56 kindreds (41%) carry mutations located in translated or untranslated exons of RPSA. Eleven of the 43 kindreds affected by sporadic disease (26%) carry RPSA mutations, whereas 12 of the 13 multiplex kindreds (92%) carry RPSA mutations. We also report that 6 of 18 (33%) protein-coding mutations and the two (100%) 5'-UTR mutations display incomplete penetrance. Three mutations were identified in two independent kindreds, due to a hotspot or a founder effect. Finally, RPSA ICA-causing mutations were demonstrated to be de novo in 7 of the 23 probands. Mutations in RPSA exons can affect the translated or untranslated regions and can underlie ICA with complete or incomplete penetrance.


Asunto(s)
Exones , Síndromes de Inmunodeficiencia/genética , Mutación , Penetrancia , Biosíntesis de Proteínas/genética , Empalme del ARN/genética , Receptores de Laminina/genética , Proteínas Ribosómicas/genética , Bazo/anomalías , Regiones no Traducidas 5' , Femenino , Efecto Fundador , Heterocigoto , Humanos , Síndromes de Inmunodeficiencia/metabolismo , Masculino , Enfermedades de Inmunodeficiencia Primaria , Receptores de Laminina/biosíntesis , Proteínas Ribosómicas/biosíntesis , Bazo/metabolismo
5.
Int J Mol Sci ; 22(21)2021 Oct 28.
Artículo en Inglés | MEDLINE | ID: mdl-34769105

RESUMEN

The epidermis is a living, multilayered barrier with five functional levels, including a physical, a chemical, a microbial, a neuronal, and an immune level. Altogether, this complex organ contributes to protect the host from external aggression and to preserve its integrity. In this review, we focused on the different functional aspects.


Asunto(s)
Epidermis/fisiología , Epidermis/microbiología , Humanos , Inmunidad , Microbiota , Células Receptoras Sensoriales/fisiología
6.
J Allergy Clin Immunol ; 139(5): 1641-1649.e6, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-27702670

RESUMEN

BACKGROUND: Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defective production of reactive oxygen species in phagocytic cells that results in life-threatening infections and severe inflammatory manifestations. The treatment of inflammatory manifestations remains challenging because it can be associated with an increased risk of infections. Previous studies have shown that phagocytes from patients with CGD display a defect in autophagy and a reactive oxygen species-independent activation of the inflammasome. OBJECTIVE: Because the intersections between autophagy and the inflammasome have been observed in patients with various diseases and microbial infections, we investigated the possible benefit of restoring the autophagy defect through rapamycin, a potent autophagy inducer, in the setting of CGD. METHODS: We studied 15 patients given a diagnosis of CGD and followed in our institution. All patients were free of any active infection at the time of the study. RESULTS: We show that patients with CGD present a consistent inflammatory phenotype defined by (1) increased nonclassical and intermediate monocytes, (2) a proinflammatory state of mononuclear phagocytes with increased IL-1ß and TNF-α content, (3) a TH17 bias of CD4+ T cells, (4) and an increase in IL-17A-secreting neutrophil numbers. We document the reversion of CGD inflammatory status by the mammalian target of rapamycin inhibitor rapamycin on the different immune cell subsets. We also provide evidence for the enhancement of rapamycin's inhibitory effect on IL-1ß secretion by the IL-1 receptor antagonist anakinra in phagocytes of patients with CGD. CONCLUSION: Altogether, these data open new therapeutic approaches for CGD-related inflammatory manifestations.


Asunto(s)
Enfermedad Granulomatosa Crónica/inmunología , Serina-Treonina Quinasas TOR/antagonistas & inhibidores , Adolescente , Adulto , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/inmunología , Niño , Preescolar , Citocinas/inmunología , Femenino , Humanos , Inmunosupresores/farmacología , Lactante , Inflamación/inmunología , Proteína Antagonista del Receptor de Interleucina 1/farmacología , Masculino , Persona de Mediana Edad , Monocitos/efectos de los fármacos , Monocitos/inmunología , Fagocitos/efectos de los fármacos , Fagocitos/inmunología , Sirolimus/farmacología , Adulto Joven
7.
Br J Haematol ; 178(3): 457-467, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28444728

RESUMEN

The BRAFV600E mutation is reported in half of patients with Langerhans cell histiocytosis (LCH). This study investigated the detection of the BRAFV600E allele in circulating cell-free (ccf) DNA in a paediatric LCH cohort. Children with BRAFV600E -mutated LCH were investigated to detect ccf BRAFV600E at diagnosis (n = 48) and during follow-up (n = 17) using a picolitre-droplet digital PCR assay. At diagnosis, ccf BRAFV600E was positive in 15/15 (100%) patients with risk-organ positive multisystem (RO+ MS) LCH, 5/12 (42%) of patients with RO- MS LCH and 3/21 (14%) patients with single-system (SS) LCH (P < 0·001, Fisher's exact test). The positive BRAFV600E load was higher for RO+ patients (mean, 2·90%; range, 0·04-11·4%) than for RO- patients (mean, 0·16%; range, 0·01-0·39) (P = 0·003, Mann-Whitney U test). After first-line vinblastine-steroid induction therapy, 7/7 (100%) of the non-responders remained positive for ccf BRAFV600E compared to 2/4 (50%) of the partial-responders and 0/4 of the complete responders (P = 0·002, Fisher's exact test). Six children treated with vemurafenib showed a clinical response that was associated with a decrease in the ccf BRAFV600E load at day 15. Thus, ccf BRAFV600E is a promising biomarker for monitoring the response to therapy for children with RO+ MS LCH or RO- LCH resistant to first-line chemotherapy.


Asunto(s)
Histiocitosis de Células de Langerhans/diagnóstico , Proteínas Proto-Oncogénicas B-raf/sangre , Adolescente , Alelos , Biomarcadores/sangre , Sistema Libre de Células/metabolismo , Niño , Preescolar , Monitoreo de Drogas/métodos , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Glucocorticoides/uso terapéutico , Histiocitosis de Células de Langerhans/tratamiento farmacológico , Histiocitosis de Células de Langerhans/genética , Humanos , Indoles/uso terapéutico , Lactante , Masculino , Mutación , Pronóstico , Proteínas Proto-Oncogénicas B-raf/genética , Sulfonamidas/uso terapéutico , Vemurafenib , Vinblastina/uso terapéutico
8.
Am J Med Genet A ; 173(7): 1858-1865, 2017 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-28488400

RESUMEN

Chromosome 7 germline macrodeletions have been implicated in human congenital malformations and developmental delays. We herein report a novel heterozygous macrodeletion of 7q34-q36.3 in a 16-year-old girl originally from West Indies. Similar to previously reported cases of germline chromosome 7q terminal deletions, our patient has dental malposition, and developmental (growth and intellectual) delay. Novel phenotypic features include endemic Kaposi sarcoma (KS), furrowed tongue, thoracolumbar scoliosis, and mild mitral valve dysplasia. The occurrence of human herpes virus 8-driven KS, in a child otherwise normally resistant to other infectious agents and without any other tumoral lesion, points to a very selective immunodeficiency. While defects in organogenesis have been described with such macrodeletions, this is the first report of immunodeficiency and cancer predisposition.

10.
J Allergy Clin Immunol ; 147(2): 734-737, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-32531373
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA